TENX — TENAX THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 34956 ·
Last close
$13.70
Market Cap
$363.39M
52W High
$19.40
52W Low
$10.25
ADV30
1,502,457
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -16,573,000 | -15,716,000 | 123,178,000 | 118,755,000 | 8,486,000 |
| Dec 2025 | 0 | — | -16,449,000 | -15,540,000 | 104,227,000 | 97,565,000 | 7,156,000 |
| Sep 2025 | 0 | — | -16,806,000 | -15,804,000 | 102,810,000 | 99,369,000 | 6,599,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,142,000
Investing CF
$0
Financing CF
$45,450,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.37
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-383,170,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-58,764,000
Pretax Income TTM
$-57,907,000
Interest Exp TTM
$0
Analysts
10
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -56,385,000 | -52,599,000 | 104,227,000 | 7,156,000 | — | -35,800,000 |
| Dec 2024 | 0 | -19,494,000 | -17,602,000 | 96,686,000 | 4,693,000 | — | -14,811,000 |
| Dec 2023 | 0 | -8,234,000 | -7,711,000 | 11,685,000 | 3,587,000 | — | -5,904,000 |
| Dec 2022 | 0 | -11,052,643 | -11,047,895 | 3,404,709 | 1,911,968 | — | -11,388,571 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.45
Max Pain — expiry 2026-08-21
max pain strike: $15.00 · spot: $13.70 · call oi: 4,511 · put oi: 6,496
Expected Move to 2026-08-21:
±$11.80
(86.13%) —
implied range
$1.90 –
$25.50
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABEO | ABEONA THERAPEUTICS INC. | $365.91M | $6.42 | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $366.39M | $12.60 | — |
| EBS | Emergent BioSolutions Inc. | $372.53M | $7.22 | — |
| NATR | NATURES SUNSHINE PRODUCTS INC | $354.34M | $20.15 | — |
| AKBA | Akebia Therapeutics, Inc. | $354.10M | $1.32 | — |
News headlines (Yahoo Finance, 1h cache)
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-31 11:00 · Yahoo
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
2026-07-21 13:55 · Yahoo
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 20:05 · Yahoo
Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June
2026-07-02 13:23 · Yahoo
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
2026-07-02 11:00 · Yahoo
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 11:00 · Yahoo
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
2026-05-04 11:00 · Yahoo
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth
2026-04-22 13:20 · Yahoo
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
2026-04-22 11:00 · Yahoo
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
2026-03-17 13:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.